Status:
COMPLETED
Long Term Quality of Life in Melanoma Patients in Netherlands
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Melanoma
Eligibility:
All Genders
18+ years
Brief Summary
Study of late physical, psychological and social effects in patients treated with ipilimumab for advanced (stage IV or unresectable stage III) melanoma.
Eligibility Criteria
Inclusion
- Inclusion Criteria-
- Patient population: Adults ≥ 18 years of age at diagnosis, diagnosed with histologically confirmed advanced (stage IV or unresectable stage III) melanoma, who have received at least one course of ipilimumab treatment (first, second, or second plus line; routine practice or study treatment) in one of the specified treatment centers, and who have survived at least 2 years after (completion of) ipilimumab treatment (measured from last ipilimumab administration)
- Matched healthy control population: Individuals without melanoma (stage III or IV) diagnosis that have been included in the PROFILES cohort
- Exclusion Criteria
- Insufficient understanding of the Dutch language
- Other anticancer treatment after ipilimumab or during study entry
- Disease recurrence during the study
- Other protocol defined inclusion/exclusion criteria could apply
Exclusion
Key Trial Info
Start Date :
December 15 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 17 2020
Estimated Enrollment :
89 Patients enrolled
Trial Details
Trial ID
NCT03450876
Start Date
December 15 2016
End Date
June 17 2020
Last Update
September 11 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Amsterdam, Netherlands, 1066 CX